Gift or transfer — classified separately from trades.
Loading…
Traded Mar 3, 2026 · Filed Mar 4, 2026
Charles River Laboratories's Corp Strategy & Develop spent $4.4K of their very own money to buy Charles River Laboratories shares.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market purchase
Code P — open-market or private purchase
~$4,364
Shares × reported transaction price
<$25K
+0.1%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
Not enough history to judge
Confirmed open-market purchases by the same insider in the available history
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
This purchase equals less than 1% of the average reported total pay of the company's named executive officers other than the CEO, fiscal 2025 ($3.56M)
An average across the officers named in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2026-03-31. This person may not be one of them, so it is not their own pay. A size comparison, not a judgement
13 days after results of Feb 18, 2026, 65 days before results of May 7, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $175.69 on Mar 3, 2026, 76% above its 52-week low and 23% below its high, after a 20% drop over the previous 30 trading days
52-week range $99.75 (Apr 11, 2025) to $226.77 (Jan 21, 2026), 60% of the way up, from 251 adjusted closes. 30 trading days earlier: $219.70 on Jan 16, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -15.8% | -2.2% | -13.6% |
| 30 days | -7.2% | -3.3% | -3.9% |
| 90 days | -0.8% | +10.7% | -11.5% |
| 180 days | +55.7% | +11.8% | +43.9% |
Past results only. Not a forecast.
Gift or transfer — classified separately from trades.
Compensation award — excluded from discretionary-purchase analysis.
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.